Growth Metrics

Moderna (MRNA) Cash from Operations (2018 - 2026)

Moderna (MRNA) has disclosed Cash from Operations for 9 consecutive years, with 630000000.0 as the latest value for Q1 2026.

  • For Q1 2026, Cash from Operations rose 39.25% year-over-year to 630000000.0; the TTM value through Mar 2026 reached 1466000000.0, up 51.97%, while the annual FY2025 figure was 1873000000.0, 37.65% up from the prior year.
  • Cash from Operations hit 630000000.0 in Q1 2026 for Moderna, down from 930000000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2763000000.0 in Q1 2022 and bottomed at 1600000000.0 in Q3 2023.
  • Average Cash from Operations over 5 years is 214352941.18, with a median of 847000000.0 recorded in 2025.
  • Year-over-year, Cash from Operations plummeted 734.92% in 2023 and then skyrocketed 45.91% in 2025.
  • Moderna's Cash from Operations stood at 1662000000.0 in 2022, then plummeted by 62.58% to 622000000.0 in 2023, then soared by 32.64% to 825000000.0 in 2024, then rose by 12.73% to 930000000.0 in 2025, then tumbled by 167.74% to 630000000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 630000000.0, 930000000.0, and 847000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.